ABT vs STE: fair value comparison
Abbott Laboratories and STERIS plc · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, STE currently sits closer to the top of our discount ranking. STE carries the stronger quality grade.
| ABT | STE | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $101.95 | $210.76 |
| 12-month range | $87.78–$128.01 | $211.07–$264.24 |
| Sector rank | #35 of 113 Healthcare | #32 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Oversold |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: ABT fair value analysis · STE fair value analysis